Optima Health (LSE:OPT) provides occupational-health and wellbeing services to employers, helping them manage staff health, meet regulatory obligations and reduce absence. Its clients span the public and private sectors, and it delivers services from clinical assessments to digital health tools. As the UK’s largest …
Uniphar operates through three divisions.SupplyChain & Retail distributes medicines and runs a pharmacy network; Product Access helps pharmaceutical companies get treatments to market, including global sourcing and clinical trial supply; andMedTechconnects medical device makers with healthcare providers. This spread means Uniphar is less dependent …
Craneware provides financial and operational software to US healthcare providers through its Trisus platform, helping them with pricing, charge capture, cost analysis and regulatory compliance. Its products aim to ensure hospitals capture theRevenuethey are entitled to and understand their true costs, in a system …
Avacta has repositioned itself as a pure-play oncology biopharmaceutical company built around its pre|CISION peptide drug conjugate platform. The idea is elegant: chemotherapy drugs are chemically modified so they only become active inside tumours, where a specific enzyme is present, sparing healthy tissue and …
NIOX makes devices that measure fractional exhaled nitric oxide, known as FeNO, a marker of airway inflammation that helps clinicians diagnose asthma and guide treatment. The company sells its devices to hospitals, clinics and researchers, and each test requires a single-use kit. This razor-and-blade …
AstraZeneca PLC — LSE:AZN closed 0.56% higher on16 September 2026, with the shares at 12,184.00p after a gain of 68.00p on the day.
GSK PLC — LSE:GSK closed 0.54% higher on16 September 2026, with the shares at 1,864.00p after a gain of 10.00p on the day.
Haleon PLC — LSE:HLN closed 0.65% lower on16 September 2026, with the shares at 338.30p after a decline of 2.20p on the day.
Smith & Nephew PLC — LSE:SN closed 0.48% lower on16 September 2026, with the shares at 1,032.50p after a decline of 5.00p on the day.
Anpario shares rose by 5.49% as investors continued to assess a positive set of interim results. The company reported higher revenue, stronger adjusted operating earnings, increased pre-tax profit and improved adjustedEarnings Per Sharedespite logistics disruption and inflationary pressure linked to the Middle East conflict.